Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2021 | Future directions & unmet needs in HCC

Philippe Merle • 14 Jan 2021
ASCO GI 2021
Gastrointestinal Cancer Liver Cancer

Philippe Merle, MD, PhD, Croix-Rousse Hospital, Lyon, France, discusses the future directions in the treatment of hepatocellular carcinoma, including safe and efficacious therapies, combinatorial approaches and personalized medicine. Prof. Merle also highlights biomarkers as an urgent area of unmet need in patients with HCC. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Philippe Merle

2:09
KEYNOTE-240: pembrolizumab in advanced HCC
Philippe Merle • 14 Jan 2021
1:15
Key updates from ASCO GI 2021
Philippe Merle • 14 Jan 2021

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals